Clinical trials: Chemo-brain
Brain and Central Nervous System Tumors
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
RATIONALE: Radioimmunotherapy uses radiolabeled monoclonal antibodies to locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00058370
- Testing
- cisplatin, lomustine, vincristine sulfate
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002676
- Testing
- carmustine, cyclophosphamide, cytarabine
- Where
- 21 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Non-Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain.
- Trial name
- NCT00390806
- Testing
- HYCAMTIN, oral capsules, Radiation
- Where
- 88 sites in United States, Canada and 4 more
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Chronic Pain, Chronic Lower Back Pain
Project Relief: Developing Brain Stimulation as a Treatment for Chronic Pain
Effective control of chronic pain is a top priority in the United States, as approximately 10% of adults have severe chronic pain most of which is chronic lower back pain (CLBP).
- Conditions
- Chronic Pain, Chronic Lower Back Pain, Back Pain, Opioid Use
- Trial name
- NCT04156802
- Testing
- Real TBS to the mPFC, Real TBS to the MC
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Serial Testing To Assess Cognitive Function In Cancer
The purpose of this study is to examine the effects of immunotherapy on cognitive function of cancer patients and follow them clinically over a period of six months with the Montreal cognitive assessment (MoCA) to assess changes…
- Trial name
- NCT06160700
- Testing
- Montreal Cognitive Assessment (MoCA)
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Indiana University
Brain and Central Nervous System Tumors, Lymphoma
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neurotoxicity
- Trial name
- NCT00734773
- Testing
- Rituximab, Cytarabine, Methotrexate
- Sponsor
- Northwestern University
Brain Metastases, Adult, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial
This pilot pragmatic trial evaluates the feasibility of avoiding radiation therapy in patients with brain metastases who demonstrate an intracranial response to systemic therapy-including immunotherapy, targeted therapy, and/or…
- Trial name
- ACTION-Brain (NCT06974370)
- Testing
- Active Surveillance
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Vermont Medical Center
Cancer
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
- Trial name
- AflacST1502 (NCT02574728)
- Testing
- Sirolimus, Celecoxib, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Brain and Central Nervous System Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- CATNON (NCT00626990)
- Testing
- temozolomide, DNA methylation analysis, laboratory biomarker analysis
- Where
- 132 sites in United States, Australia and 10 more
- Volunteers
- 751 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors, Seizure
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors
RATIONALE: Levetiracetam and pregabalin are drugs that treat seizures. It is not yet known which drug is more effective in treating seizures caused by primary brain tumors.
- Trial name
- NCT00629889
- Testing
- levetiracetam, pregabalin
- Where
- 2 sites in Switzerland
- Volunteers
- 52 people
- Sponsor
- Dr Andrea Rossetti
Lymphoma
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, etoposide phosphate, dexamethasone, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- Protocol-B (NCT00074178)
- Testing
- filgrastim, pegfilgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- OHSU Knight Cancer Institute
Brain and Central Nervous System Tumors
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or…
- Trial name
- NCT00003101
- Testing
- filgrastim, busulfan, lomustine
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer Stage II, Bevacizumab
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases
A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases
- Conditions
- Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy, Brain Metastases
- Trial name
- SUPER BRAIN (NCT05807893)
- Testing
- Serplulimab combined with bevacizumab and first-line chemotherapy
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-Small-Cell Lung Cancer
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
This study is a randomized, double-blind, placebo-controlled, multi-center clinical study. Target population is patients with stage IV non-small cell lung cancer who had not received systemic chemotherapy.
- Trial name
- NCT04768075
- Testing
- Camrelizumab, Cisplatin, Carboplatin
- Where
- 14 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangdong Association of Clinical Trials
NSCLC Stage IV, Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
- Conditions
- NSCLC Stage IV, Brain Metastases, Immunotherapy
- Trial name
- NCT04291092
- Testing
- Immunotherapy, WBRT, Chemotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Brain and Central Nervous System Tumors
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392886
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 37 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Children's Hospital Los Angeles
Early Breast Cancer
Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer
Primary Objective To investigate and clearly document the presence and extent of cognitive decline, if any, in women of Asian origin following standard-dose systematic adjuvant chemotherapy for the treatment of breast cancer…
- Trial name
- NCT00713141
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Brain and Central Nervous System Tumors
Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00303810
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- Germany
- Volunteers
- 567 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf